These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26917691)

  • 1. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.
    Chertow GM; Liu J; Monda KL; Gilbertson DT; Brookhart MA; Beaubrun AC; Winkelmayer WC; Pollock A; Herzog CA; Ashfaq A; Sturmer T; Rothman KJ; Bradbury BD; Collins AJ
    J Am Soc Nephrol; 2016 Oct; 27(10):3129-3138. PubMed ID: 26917691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.
    Park H; Desai R; Liu X; Smith SM; Hincapie-Castillo J; Henry L; Goodin A; Gopal S; Pepine CJ; Mohandas R
    Clin J Am Soc Nephrol; 2022 Jun; 17(6):851-860. PubMed ID: 35589388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis.
    Desai R; Unigwe I; Riaz M; Smith SM; Shukla AM; Mohandas R; Jeon N; Park H
    Clin Pharmacol Ther; 2024 Jul; 116(1):217-224. PubMed ID: 38629679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.
    Palmer SC; Saglimbene V; Mavridis D; Salanti G; Craig JC; Tonelli M; Wiebe N; Strippoli GF
    Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010590. PubMed ID: 25486075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
    Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
    Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Bieber BA; Pisoni RL; Li Y; Morgenstern H; Akizawa T; Jacobson SH; Locatelli F; Port FK; Robinson BM
    J Am Soc Nephrol; 2016 Jul; 27(7):2205-15. PubMed ID: 26582402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
    Koulouridis I; Alfayez M; Trikalinos TA; Balk EM; Jaber BL
    Am J Kidney Dis; 2013 Jan; 61(1):44-56. PubMed ID: 22921639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare.
    Wang C; Kane R; Levenson M; Kelman J; Wernecke M; Lee JY; Kozlowski S; Dekmezian C; Zhang Z; Thompson A; Smith K; Wu YT; Wei Y; Chillarige Y; Ryan Q; Worrall C; MaCurdy TE; Graham DJ
    JAMA Intern Med; 2016 Dec; 176(12):1818-1825. PubMed ID: 27775769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates.
    Molony JT; Monda KL; Li S; Beaubrun AC; Gilbertson DT; Bradbury BD; Collins AJ
    Am J Kidney Dis; 2016 Aug; 68(2):266-276. PubMed ID: 26980607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
    Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study.
    Monda KL; Joseph PN; Neumann PJ; Bradbury BD; Rubin RJ
    BMC Nephrol; 2015 May; 16():67. PubMed ID: 25928734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J; Agarwal A; Huang F; Gitlin M; Gandra SR; Cangialose CB
    J Manag Care Pharm; 2009; 15(9):741-50. PubMed ID: 19954265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.
    Thamer M; Zhang Y; Kshirsagar O; Cotter DJ; Kaufman JS
    Am J Kidney Dis; 2014 Nov; 64(5):706-13. PubMed ID: 25011692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013.
    Coritsidis GN; Maglinte GA; Acharya A; Saxena A; Chang CL; Hill J; Gitlin M; Lafayette RA
    Clin Ther; 2014 Mar; 36(3):408-18. PubMed ID: 24582713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.
    Kuwahara M; Hasumi S; Mandai S; Tanaka T; Shikuma S; Akita W; Mori Y; Sasaki S
    Clin Exp Nephrol; 2014 Oct; 18(5):755-62. PubMed ID: 24317507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.